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The ability to maintain skeletal muscle mass appears
to be impaired in insulin-resistant conditions, such as
type 2 diabetes, that are characterized by muscle lipid
accumulation. The current study investigated the
effect of acutely increasing lipid availability on muscle
protein synthesis. Seven healthy young male vol-
unteers underwent a 7-h intravenous infusion of
L-[ring-2H5]phenylalanine on two randomized occa-
sions combined with 0.9% saline or 10% Intralipid at
100mL/h. After a 4-h “basal” period, a 21-g bolus of amino
acids was administered and a 3-h hyperinsulinemic-
euglycemic clamp was commenced (“fed” period). Mus-
cle biopsy specimens were obtained from the vastus
lateralis at 1.5, 4, and 7 h. Lipid infusion reduced fed
whole-body glucose disposal by 20%. Furthermore,
whereas the mixed muscle fractional synthetic rate in-
creased from the basal to the fed period during saline
infusion by 2.2-fold, no change occurred during lipid
infusion, despite similar circulating insulin and leucine
concentrations. This “anabolic resistance” to insulin
and amino acids with lipid infusion was associated
with a complete suppression of muscle 4E-BP1 phos-
phorylation. We propose that increased muscle lipid
availability may contribute to anabolic resistance in
insulin-resistant conditions by impairing translation
initiation.
It has been proposed that the inability of skeletal muscle
to adequately synthesize new protein in response to
anabolic stimuli, such as amino acids (termed “anabolic
resistance”), is a key contributory factor to the muscle
mass loss observed in a variety of conditions such as
aging, type 2 diabetes, disuse, and critical illness (1,2). A
common feature of all of these conditions is the inability
of skeletal muscle glucose metabolism to respond ade-
quately to insulin signaling (insulin resistance), which is
thought to be a consequence of the intracellular accumu-
lation of lipid within skeletal muscle (3). Because insulin
signaling is also integral to skeletal muscle amino acid
delivery and metabolism, in particular playing a permissive
role in regulating muscle protein synthesis via activation
of the mammalian target of rapamycin complex 1 (mTOR)
pathway (4,5), it is possible that lipid-induced insulin re-
sistance may contribute toward skeletal muscle anabolic
resistance. Indeed, skeletal muscle protein synthesis in
response to insulin and amino acids appears to be nega-
tively related to whole-body fat mass and insulin sensitiv-
ity in humans (6). Thus, it is important to elucidate the
effect of excess lipid per se on insulin- and amino acid–
stimulated skeletal muscle protein synthesis and the as-
sociated signaling pathways in vivo in humans, particu-
larly if strategies to treat anabolic resistance are to focus
on reducing skeletal muscle lipid accumulation and insulin
resistance.
The intravenous infusion of a lipid emulsion with
heparin is routinely used to elevate free fatty acid
availability and allows researchers to investigate the
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acute effects of lipid-induced insulin resistance on
insulin signaling (7) and subsequent impairments in
glucose uptake, storage, and oxidation (8,9). The cur-
rent study investigated the effect of acutely elevating
fatty acid availability to a concentration known to in-
duce insulin resistance of glucose metabolism on the
muscle protein synthetic response and associated sig-
naling to amino acid ingestion in the presence of a con-
trolled, steady-state circulating insulin concentration in
humans.
RESEARCH DESIGN AND METHODS
Subjects
Seven healthy male participants (age 23.0 6 0.8 years,
body mass 78.5 6 3.8 kg, BMI 24.5 6 0.9 kg/m2) gave
their written informed consent to participate in the cur-
rent study, which was approved by the University of
Nottingham Medical School Ethics Committee in accor-
dance with the Declaration of Helsinki.
Protocol
Participants reported to the laboratory at 0800 on two
randomized occasions, at least 2 weeks apart, after an
overnight fast and having abstained from strenuous exer-
cise for the previous 48 h. On each visit, the participants
rested semisupine on a bed while a 7-h intravenous
infusion of L-[ring-2H5]phenylalanine (0.5 mg $ kg
21 $ h21;
Cambridge Isotopes Laboratories, Tewksbury, MA) was
performed in combination with the infusion of 0.9%
saline (“control”) or 10% Intralipid (“lipid”; Fresenius
Kabi, Bad Homburg, Germany) at a rate of 100 mL/h.
During the lipid infusion, heparin was infused at rate of
600 units/h to elevate plasma nonesteriﬁed fatty acid
(NEFA) availability. After 4 h, a 21-g bolus of amino
acids (except phenylalanine and tyrosine; Tyrosidon, SHS
Figure 1—Plasma NEFA concentration (A), plasma insulin concentration (B), whole-body glucose disposal (C), and PDCa (D) before (basal
1.5–4 h) and after (fed 4–7 h) the administration of 21 g amino acids and a 3-h hyperinsulinemic-euglycemic (;100 mU/L) clamp during
a 7-h intravenous infusion of saline (control) or 10% Intralipid (lipid) at a rate of 100 mL/h. Values represent means 6 SEM. †††P < 0.001,
††P < 0.01, †P < 0.05, lipid signiﬁcantly different from corresponding control value. ***P < 0.001, control and lipid during fed signiﬁcantly
different from corresponding basal steady state.
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International Ltd., Liverpool, U.K.) was administered in a
440-mL solution via a nasogastric tube to avoid issues
with palatability. At the same time, a 3-h hyperin-
sulinemic (Actrapid; Novo Nordisk, Aalborg Øst, Den-
mark) euglycemic (20% dextrose; Baxter Healthcare,
Thetford, U.K.) clamp (10) was commenced at a rate of
50 mU $ m22 $ min21. At t = 7 h, the Intralipid/saline,
L-[ring-2H5]phenylalanine, and insulin infusions were
stopped, whereas the glucose infusion was continued un-
til the blood glucose concentration was stable.
Sample Collection and Analysis
Arterialized venous blood was obtained from a heated
hand vein (11) at t = 0, 1.5 h, and every 30 min thereafter.
Plasma treated with tetrahydrolipostatin (30 mg/mL
plasma) was analyzed for NEFA (NEFA C kit; WAKO
Chemicals, Düsseldorf, Germany) on an automated ana-
lyzer (ABX Pentra 400; Horiba Medical Ltd., Montpellier,
France). Plasma separated from EGTA-treated blood was
analyzed for insulin concentration by ELISA (DRG Diag-
nostics, Marburg, Germany) and, after deproteinization
on ice with dry 5-sulfosalicylic acid, phenylalanine, and
leucine concentration, and L-[ring-2H5]phenylalanine en-
richment by gas chromatography–mass spectrometry
(Agilent 7890A GC/5975C; MSD, Little Falls, NY), as pre-
viously described (12,13).
Muscle samples were obtained from the vastus lateralis
at t = 1.5, 4, and 7 h using the Bergström needle biopsy
technique and immediately frozen in liquid nitrogen.
Freeze-dried muscle separated free of visible blood, fat,
and connective tissue was analyzed for intracellular tissue
free and protein-bound L-[ring-2H5]phenylalanine enrich-
ments (12,13), as well as acetylcarnitine and long-chain
acyl-CoA (t = 1.5 and 7 h only), as previously described
(9). The remaining “wet” muscle was used to measure
the total muscle protein content (t = 4 and 7 h only) of
phosphorylated Akt (serine473), mTOR (serine2448), and
4E-BP1 (threonine37/46) by Western blot analysis using
commercial antibodies (Cell Signaling, Danvers, MA) nor-
malized to a-actin (Sigma-Aldrich Company Ltd., Dorset,
U.K.) to control for loading, as well as pyruvate dehydro-
genase complex activation (PDCa) status, both as de-
scribed previously (9).
Calculations
The mixed muscle protein fractional synthesis rate (FSR)
was calculated by dividing the increment in enrichment in
the product (i.e., protein-bound L-[ring-2H5]phenylalanine)
by the enrichment of the precursor (i.e., plasma free
L-[ring-2H5]phenylalanine) (13). To adjust for nonsteady-
state plasma tracer enrichments during the fed period,
precursor enrichments were calculated as the integral of
the plasma L-[ring-2H5]phenylalanine enrichment (14,15).
Figure 2—Plasma leucine concentration (A), plasma phenylalanine
concentration (B), and plasma L-[ring-2H5]phenylalanine enrichment
(C ) before (basal 1.5–4 h) and after (fed 4–7 h) the administration of
21 g amino acids and a 3-h hyperinsulinemic-euglycemic (;100
mU/L) clamp during a 7-h intravenous infusion of saline (control)
or 10% Intralipid (lipid) at a rate of 100 mL/h. Values represent
means 6 SEM. MPE, mole percent excess. †††P < 0.001, lipid
signiﬁcantly lower than corresponding control value. ***P < 0.001,
**P < 0.01, control and lipid during fed signiﬁcantly different from
corresponding basal values.
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Statistics
A two-way ANOVA (time and treatment factors) was
performed using GraphPad Prism 6 software (GraphPad
Software Inc., San Diego, CA) to detect differences within and
between groups for all measures described. When a signiﬁcant
effect was observed, a Student t test with Bonferroni correc-
tion was performed to locate differences. Statistical signiﬁ-
cance was declared at P, 0.05. All of the values presented in
the text, tables, and ﬁgures represent the means 6 SEM.
RESULTS
Insulin Resistance of Glucose Metabolism
Steady-state plasma NEFA concentrations were elevated
throughout the basal period in lipid compared with control
(P , 0.001; Fig. 1A). Furthermore, plasma NEFA concen-
trations were suppressed (P, 0.001) by insulin and amino
acid administration to a similar degree (20.38 6 0.01 vs.
20.39 6 0.01 mmol/L; Fig. 1A), such that they remained
greater in lipid throughout the fed period (P , 0.001; Fig.
1A). This similar suppression of plasma NEFA concentra-
tion between lipid and control was reﬂected by similar
steady-state blood glucose (4.51 6 0.05 vs. 4.52 6 0.05
mmol/L, respectively) and plasma insulin concentrations
(1046 5 vs. 996 3 mU/L, respectively; Fig. 1B). However,
there was a 206 6% lower average glucose disposal during
the ﬁnal hour of the fed period in lipid compared with
control (P , 0.01; Fig. 1C) and a 56 6 12% lower PDCa
by the end of the fed period at 7 h (P , 0.05; Fig. 1D).
Amino Acid and Lipid Metabolism
Plasma leucine and phenylalanine concentrations (Fig. 2A
and B, respectively) were both maintained at fasting con-
centrations throughout the basal period in lipid and control.
Similarly, plasma L-[ring-2H5]phenylalanine enrichments
remained at the same steady-state levels in lipid and control
(Fig. 2C). Insulin and amino acid administration resulted in
a similar peak in plasma leucine concentration in lipid and
control after 30 min of the fed period (P , 0.001; Fig. 2A).
However, insulin and amino acid administration caused
a steady decline in the plasma phenylalanine concentration
during control, such that it was 49 6 3% lower during the
ﬁnal hour of the fed period compared with basal (P ,
0.001; Fig. 2B). Furthermore, the degree of reduction in
the plasma phenylalanine concentration in response to in-
sulin and amino acid administration was greater in lipid
(65 6 3%; P , 0.001) than in control, such that the
steady-state phenylalanine concentrations were lower (P ,
0.001; Fig. 2B). However, this did not result in a greater
L-[ring-2H5]phenylalanine enrichment during the ﬁnal hour
of the fed period in lipid compared with control (Fig. 2C).
Basal mixed muscle FSR was the same in lipid compared
with control (Fig. 3A). However, mixed muscle FSR in-
creased from the basal to the fed period in control (P ,
0.05; Fig. 3A) but did not respond to insulin and amino
acid administration in lipid, such that it was signiﬁcantly
lower than control (P , 0.05; Fig. 3A). This was despite
similar intracellular muscle enrichment before and after
Figure 3—Skeletal mixed muscle protein FSR (A), long-chain acyl-
CoA content (B), and acetylcarnitine content (C ) before (basal)
and after (fed) the administration of 21 g amino acids and a 3-h
hyperinsulinemic-euglycemic (;100 mU/L) clamp during a 7-h
intravenous infusion of saline (control) or 10% Intralipid (lipid) at a
rate of 100 mL/h. Values represent means 6 SEM. †P < 0.05, ††P
< 0.01, lipid signiﬁcantly lower than the corresponding control value.
*P < 0.05, ***P < 0.001, fed signiﬁcantly greater than corresponding
basal values.
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insulin and amino acid administration (4.4 6 0.3 to 6.0 6
0.3 vs. 4.6 6 0.3 to 5.9 6 0.6 mole percent excess for lipid
and control, respectively). Furthermore, this lower rate of
protein synthesis in lipid coincided with an inhibition of
the insulin- and amino acid–mediated decline in skeletal
muscle long-chain acyl-CoA (P , 0.05; Fig. 3B) and acetyl-
carnitine (P , 0.01; Fig. 3C) content at t = 7 h in control.
Associated Muscle-Signaling Pathways
The phosphorylation status of Akt, mTOR, and 4E-BP1
were the same after the basal period at t = 4 h in lipid
compared with control. Insulin and amino acid adminis-
tration increased the phosphorylation of Akt (P , 0.05;
Fig. 4A), mTOR (P , 0.01; Fig. 4B), and 4E-BP1 (P ,
0.001; Fig. 4C) by 1.9-, 1.7-, and 2.9-fold, respectively,
compared with basal in control. However, insulin and
amino acid administration also increased mTOR phos-
phorylation by 1.5-fold from basal in lipid (P , 0.05;
Fig. 4B), but the 1.8-fold increase in Akt phosphorylation
was not signiﬁcantly different (P = 0.09; Fig. 4A). Further-
more, lipid infusion had no effect on 4E-BP1 phosphory-
lation, such that it was less than half that of control at the
end of the fed period (P , 0.01; Fig. 4C).
DISCUSSION
The concept that lipid-induced insulin resistance coin-
cides with anabolic resistance is not new. Diet-induced
obesity in mice (16) and rats (17) was shown to impair the
activation of skeletal muscle protein synthesis in response
to feeding, particularly in glycolytic muscle where there
was chronic lipid inﬁltration (17). The whole-body protein
anabolic response to combined hyperinsulinemia and
hyperaminoacidemia is also blunted in obese women com-
pared with lean individuals (18), and skeletal muscle pro-
tein synthesis in response to insulin and amino acids
appears to be negatively related to whole-body fat mass
in humans (6). However, the contribution of excess lipid
and insulin resistance to anabolic resistance cannot be
determined from the associations described above be-
cause other confounding factors, particularly physical ac-
tivity status, will also contribute to anabolic resistance
(2,19). Thus, the current study clearly demonstrates
that excess lipid availability per se within skeletal muscle
can induce insulin resistance of skeletal muscle glucose
metabolism and also anabolic resistance of amino acid
metabolism independently of physical activity levels and
diet-induced changes in body composition. This was evi-
denced by reduced insulin-stimulated peripheral glucose
disposal and skeletal muscle PDCa by ;20 and 50%, re-
spectively, and a complete prevention of a 2.2-fold in-
crease in the rate of mixed muscle protein synthesis in
response to the ingestion of 21 g amino acids containingFigure 4—Representative blots (top panel) and phosphorylation (p)
status of skeletal muscle Akt serine473 (A), mTOR serine2448 (B),
and 4E-BP1 threonine37/46 (C) before (basal) and after (fed) the
administration of 21 g amino acids (AA) and a 3-h hyperinsulinemic-
euglycemic (;100 mU/L) clamp during a 7-h intravenous infusion of
saline (control) or 10% Intralipid (lipid) at a rate of 100 mL/h. Values
represent means 6 SEM. AU, arbitrary units. ††P < 0.01, lipid
signiﬁcantly lower than corresponding control value. ***P < 0.001,
**P < 0.01, * P < 0.05, fed signiﬁcantly greater than corresponding
basal values.
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2.3 g leucine. Furthermore, this inability of skeletal mus-
cle to increase protein synthesis in response to insulin
and amino acid administration appeared to be partly me-
diated by the repression of translation initiation at the
level of 4E-BP1, which is in agreement with previous
studies demonstrating that elevating lipid availability in
rats and cells decreases muscle protein synthesis (20,21).
This is, to our knowledge, the ﬁrst study to acutely
induce anabolic resistance in humans by lipid adminis-
tration. However, these ﬁndings are in contrast to the
study of Katsanos et al. (22), where lipid was intrave-
nously administered at nearly twice the rate and no blunt-
ing of the 50% increase in muscle protein synthesis was
observed in response to the ingestion of 7 g essential
amino acids. The differences are difﬁcult to reconcile
but may be due to the hyperinsulinemic-euglycemic clamp
in the current study, which likely impaired fat oxidation
and caused an accumulation of intracellular lipid metab-
olites (23). Indeed, this was reﬂected by greater muscle
long-chain acyl-CoA and acetylcarnitine content during
lipid infusion under insulin- and amino acid–stimulated
conditions, which are sensitive markers of incomplete
lipid oxidation and lipid accumulation (9,24). Although
a mechanistic link has not been established, these results
offer compelling evidence that a common lipid-mediated
intracellular signaling defect downstream of the Akt-
mTOR signaling pathway may cause both lipid-induced
insulin and anabolic resistance and provide insight into
how conditions of lipid-induced insulin resistance, such as
aging, type 2 diabetes, disuse, and critical illness, may be
linked to accelerated muscle mass loss.
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